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Abstract
Background: Combination therapy in managing psychiatric disorders is not uncommon. While
combination therapy has been documented for depression and schizophrenia, little is known about
combination therapy practices in managing attention-deficit/hyperactivity disorder (ADHD). This
study seeks to quantify the combination use of ADHD medications and to understand predictors
of combination therapy.
Methods:  Prescription dispensing events were drawn from a U.S. national claims database
including over 80 managed-care plans. Patients studied were age 18 or over with at least 1 medical
claim with a diagnosis of ADHD (International Classification of Diseases, Ninth Revision, Clinical
Modification [ICD-9-CM] code 314.0), a pharmacy claim for ADHD medication during the study
period July2003 to June2004, and continuous enrollment 6 months prior to and throughout the
study period. Dispensing events were grouped into 6 categories: atomoxetine (ATX), long-acting
stimulants (LAS), intermediate-acting stimulants (IAS), short-acting stimulants (SAS), bupropion
(BUP), and Alpha-2 Adrenergic Agonists (A2A). Events were assigned to calendar months, and
months with combined use from multiple categories within patient were identified. Predictors of
combination therapy for LAS and for ATX were modeled for patients covered by commercial plans
using logistic regression in a generalized estimating equations framework to adjust for within-
patient correlation between months of observation. Factors included age, gender, presence of the
hyperactive component of ADHD, prior diagnoses for psychiatric disorders, claims history of
recent psychiatric visit, insurance plan type, and geographic region.
Results: There were 18,609 patients identified representing a total of 11,886 months of therapy
with ATX; 40,949 months with LAS; 13,622 months with IAS; 38,141 months with SAS; 22,087
months with BUP; and 1,916 months with A2A. Combination therapy was present in 19.7% of
continuing months (months after the first month of therapy) for ATX, 21.0% for LAS, 27.4% for
IAS, 23.1% for SAS, 36.9% for BUP, and 53.0% for A2A.
For patients receiving LAS, being age 25–44 or age 45 and older versus being 18–24 years old,
seeing a psychiatrist, having comorbid depression, or having point-of-service coverage versus a
Published: 8 June 2009
BMC Health Services Research 2009, 9:95 doi:10.1186/1472-6963-9-95
Received: 14 April 2008
Accepted: 8 June 2009
This article is available from: http://www.biomedcentral.com/1472-6963/9/95
© 2009 Pohl et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Health Services Research 2009, 9:95 http://www.biomedcentral.com/1472-6963/9/95
Page 2 of 8
(page number not for citation purposes)
Health Maintenance Organization (HMO) resulted in odds ratios significantly greater than 1,
representing increased likelihood for combination therapy in managing adult ADHD.
For patients receiving ATX, being age 25–44 or age 45 and older versus being 18–24 years old,
seeing a psychiatrist, having a hyperactive component to ADHD, or having comorbid depression
resulted in odds ratios significantly greater than 1, representing increased likelihood for
combination therapy in managing adult ADHD.
Conclusion:  ATX and LAS are the most likely drugs to be used as monotherapy. Factors
predicting combination use were similar for months in which ATX was used and for months in
which LAS was used except that a hyperactive component to ADHD predicted increased
combination use for ATX but not for LAS.
Background
Attention-deficit/hyperactivity disorder (ADHD) is a psy-
chiatric disorder that originates in childhood and often
continues into adulthood. It has been estimated that
between 3% and 10% of all children are affected by
ADHD and that 33% to 66% of these children have
ADHD symptoms into adulthood [1]. The disorder is
characterized by persistent inattention, impulsive hyper-
activity, or both [2] and is often comorbid with a number
of other psychiatric disorders [3-5]. These symptoms lead
to a number of impairments, with adults diagnosed with
ADHD being less likely to graduate high school or college,
hold employment, or report having life satisfaction [6].
Medications are commonly used to manage ADHD. Most
often used are stimulants that interact with brain
monoamine systems. These include amphetamines
(Dexedrine or Adderall) and methylphenidate (Concerta,
Ritalin, or Focalin). Nonstimulant medications include
atomoxetine (Strattera) and bupropion (Wellbutrin) [7].
Stimulants like amphetamines and methylphenidate are
highly effective pharmacological treatments for ADHD
and are used as "first-line" agents for managing this disor-
der [7,8]. Atomoxetine also improves ADHD symptoms,
but may not be as fast acting or effective as amphetamines
or methylphenidate for addressing acute behavioral con-
cerns [7,9-11]. Although these medications have proven
effective in managing ADHD to varying degrees, there are
some patients who do not respond favorably to any single
medication and may require a combination of treatments
to manage ADHD [12,13].
Polypharmacy (combination therapy) in managing psy-
chiatric disorders is not uncommon [14-17]. Indeed,
patients with treatment-resistant depression or schizo-
phrenia often receive combinations of medications to
alleviate their symptoms. In 1 study, for example, patients
that had greater severity of symptoms were more likely to
be treated with multiple medications upon discharge
from an inpatient psychiatric unit [14]. While combina-
tion therapy has been documented for depression and
schizophrenia, little is known about combination therapy
practices in managing ADHD. Results of a recent chart
review do indicate that combination therapy for adult
ADHD is used to prolong therapeutic effects or manage
primary medication side effects [18].
The purpose of the present study is to examine the preva-
lence of combination therapy in adults with ADHD using
a retrospective claims analysis of data from a large data
warehouse. These data are also used to determine which
demographic or utilization patterns, if any, predict combi-
nation therapy in adult ADHD patients receiving either
long-acting stimulants or atomoxetine. We focus on these
medications as they represent the most comparable treat-
ments in terms of duration of action and represent the
newest additions and possibly most costly therapies. Note
that our perspective is not clinical. We make no claims or
recommendations regarding the effectiveness of combina-
tion therapy or the tradeoffs in terms of cost or increased
exposure to potential side effects of medication. Instead,
our research is an examination from the health systems
perspective, where combination use may be seen as dupli-
cative or an indication that existing resources are not
being used to maximal effect.
Methods
This study was a retrospective claims analysis of data
obtained from the commercially available PharMetrics,
Inc. data warehouse on October 6, 2005. Medication
usage was analyzed for the period from July 2003 to June
2004. These data reflect U.S. national medical and phar-
macy claims covering more than 80 managed-care organ-
izations and 60 million beneficiaries. All data received
had been previously de-identified so as to maintain the
confidentiality of patients. This study was conducted in
compliance to all requirements of the Health Insurance
Portability and Accountability Act (HIPAA).
The initial subset drawn included all patients (2,041,434)
with at least 1 medical claim with a diagnosis of ADHD
(ICD9-CM code 314.0). We narrowed the focus toBMC Health Services Research 2009, 9:95 http://www.biomedcentral.com/1472-6963/9/95
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patients who were enrolled 6 months prior to and
throughout the study period (435,536: 21.3%). From
these, we identified patients 18 years or older in 2003
(305,469: 70.1%). Finally, we determined which of those
patients had a prescription for an ADHD medication dur-
ing the study period (18,609: 6.1%). This was the basis for
our final analysis group. It is important to note that while
demographics are given for the individuals included in
the study, the unit of analysis is patient-months during
which individuals received a prescription for an ADHD
medication.
Data were analyzed as patient-months of treatment on
any given class of medication, and each calendar month
of treatment was characterized as being associated with
either monotherapy or combination use of medications.
Patient-level claims were assigned based on the date of
service and days' supply. Supplies of less than or equal to
31 days were assigned to a single month; supplies of 32 to
60 days, to 2 months; and 61 to 90, to 3 months and so
on. The starting month was taken to be the month of the
claim if a greater portion of the supply was available in
that month than in the last succeeding month covered by
the claim. Otherwise, the starting month was shifted to
the month immediately following the claim date. In addi-
tion, to focus on long-term combination therapy rather
than details of transitional management (tapering,
unused leftover supply, etc.), the first month of each con-
tinuous treatment episode was excluded from analysis.
As shown in Table 1, the analysis divided medications
used to treat ADHD into 6 classes: long-acting stimulants
Table 1: ADHD Drug Classes as Defined in This Study.
Drug Class Medications Included
Atomoxetine Strattera
Long-Acting Stimulants (LAS) Ritalin LA
Metadate CD
Concerta
Focalin XR
Adderall XR
Generic pemoline
Cylert
Intermediate-acting Stimulants (IAS) Generic methylphenidate (ER/SR/CR/SA)
Ritalin SR
Metadate ER
Methylin ER
Generic amphetamines (CR)
Adderall
Dexedrine spansules
Desoxyn
Short-Acting Stimulants (SAS) Generic methylphenidate (short-acting)
Ritalin
Methylin
Focalin
Generic amphetamines
Dexedrine
Dextrostat
Dexampex
Biphetamine
Provigil
Buproprion (BUP) Generic bupropion (SR/ER)
Generic bupropion
Wellbutrin
Wellbutrin SR
Wellbutrin XL
Zyban
Alpha-2 Adrenergic Agonists (A2A) Clonidine
GuanfacineBMC Health Services Research 2009, 9:95 http://www.biomedcentral.com/1472-6963/9/95
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(LAS), intermediate-acting stimulants (IAS), short-acting
stimulants (SAS), atomoxetine (ATX), buproprion (BUP),
and alpha-2 adrenergic agonists (A2A). Although BUP
and A2A are not indicated for ADHD, they have been used
"off-label" to treat ADHD [7,19] and were included in this
analysis.
We determined the predictors of combination therapy
separately for LAS and ATX in those patients covered by
commercial plans. To adjust for correlation within the
months of treatment in the same patient, logistic regres-
sion was performed in a general estimating equations
framework with exchangeable covariance structure
between months within patient. Factors included in the
models were age, gender, presence of hyperactive compo-
nent to the ADHD, prior claim diagnoses for various psy-
chiatric disorders, claims history of prior psychiatric visit,
insurance plan type, and geographic region. Diagnoses
were considered positive if seen in 2 claims on separate
days in the 6 months prior to study period, and psychiat-
ric service use was considered positive if seen in 1 claim
prior to study period.
Analyses were performed using the SAS® system version
8.02 for Unix (Cary, North Carolina) with predictive
models fit using PROC GENMOD. Confidence intervals
are reported at the 95% level.
Results
Demographics
Demographic characteristics of patients contributing pre-
scription events are presented in Table 2.
Medications and Medication Combinations for ADHD
Total patient months of LAS, IAS, or SAS treatment were
40,949; 13,622; and 38,141, respectively. Total patient
months of the nonstimulants – ATX, BUP, or A2A – were
11,886; 22,087; and 1,916, respectively. Of these, 34,239;
11,200; 31,239; 8,141; 18,318; and 1,639 were months
following the first months of usage for each medication
class (Table 3).
When analyzed in terms of combination months (i.e.,
non-first months in which patients received more than 1
medication for ADHD), patients received medication
combinations 21.0% of months for LAS, 27.4% of
months for IAS, and 23.1% of months for SAS (Table 3).
Patients received medication combinations 19.7% of
months for ATX, 36.9% of months for BUP, and 53.0% of
months for A2A.
Stimulants and ATX appeared in combination with BUP
approximately 8–9% of months. Excluding BUP, ATX was
used most frequently in combination with LAS (6.7% of
months); LAS, most frequently with SAS (9.5% of
months); IAS, with SAS (17.1% of months); and SAS with
LAS (9.1% of months).
Predictors of Combination Therapy in Adult ADHD
Adjusted odds ratios for various factors predicting
whether a given month of therapy would be a month in
which multiple medications were received are presented
in Figure 1. Note while interpreting the 2 models, that the
ATX model is based on a much smaller sample size and,
therefore, has much broader confidence intervals than the
LAS model. Caution should, therefore, be exercised in
interpreting factors that are significant only in the LAS
model but not the ATX model.
For patients receiving LAS, being age 25–44 or age 45 and
older versus being 18–24 years old, seeing a psychiatrist,
having comorbid depression, or having point of service
coverage versus a Health Maintenance Organization
Table 2: Demographic Characteristics of Patients (N = 18,609) 
Included in This Analysis.
Variable Percentage
Age in Years
18–24 38.33%
25–44 34.99%
45 and older 26.68%
Gender
Male 54.44%
Female 45.56%
Prior Claim Diagnoses (ICD9-CM codes)
ADHD Hyperactive Type (314.01) 30.91%
Psychotic Disorders (295, 297, 298) 1.30%
Bipolar/Mania
(296.0, 296.1, 296.4, 296.5 – 8,301.13) 5.63%
Depression (296.2, 296.3, 300.4, 311) 38.48%
Anxiety States (300) 19.85%
Personality Disorders (301) 1.98%
Tics/Tourette's (307.2) 0.40%
Substance Abuse/Dependence (303 – 305) 10.80%
Eating Disorders (307.1, 307.50 – 307.51) 0.87%
Psychiatric Visit in Prior 6 Months 24.88%
Payer Type
Commercial Plan 92.04%
Medicaid 2.72%
Self-Insured 2.91%
Other/Unknown 2.33%
Plan Type
HMO 49.13%
Preferred Provider 31.65%
Point of Service 12.66%
Indemnity 4.33%
Other/Unknown 2.24%
Region
Midwest 56.08%
South 25.43%
East 12.14%
West 6.35%BMC Health Services Research 2009, 9:95 http://www.biomedcentral.com/1472-6963/9/95
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(HMO) resulted in odds ratios significantly greater than 1,
representing increased likelihood for combination ther-
apy in managing adult ADHD.
For patients receiving ATX, being age 25–44 or age 45 and
older versus being 18–24 years old, seeing a psychiatrist,
having a hyperactive component to ADHD, or having
comorbid depression resulted in odds ratios significantly
greater than 1, representing increased likelihood for com-
bination therapy in managing adult ADHD.
Discussion
The results of the present study indicate that combination
therapy in adult ADHD is not uncommon. Combination
therapy was present in more than 20% of the months of
therapy represented in this sample. Approximately 8–9%
of the combination therapy of stimulants and of ATX was
with BUP. This may not represent true combination ther-
apy for treatment of ADHD but may rather reflect treat-
ment of comorbid conditions, particularly depression.
Combination therapy was least common in patients pre-
scribed LAS and in patients prescribed ATX. For patients
prescribed BUP or A2A, combination therapy was much
more common. Interestingly, for patients prescribed BUP
and A2A, the supplemental medications were most often
stimulants.
The finding that combination therapy is not as common
for patients prescribed stimulants relative to BUP and
A2A, despite that these medications were the class most
often prescribed is consistent with the use of these indi-
cated drugs as "first line" agents for adult ADHD [7]. BUP
and A2A, on the other hand, may well be used in this
adult sample to treat conditions other than ADHD, and
their presence here may in part reflect psychiatric comor-
bidities in addition to ADHD treatment. Interestingly,
despite debates [7-10] over its efficacy, ATX was not used
more often in combination therapy than the stimulants.
IAS showed markedly more combination use with SAS
than either LAS or ATX. This may reflect the more limited
duration of action of IAS being insufficient to maintain
adequate ADHD symptom control throughout the entire
day.
To better understand the factors that contributed to com-
bination therapy in patients prescribed long-acting
ADHD medications, specifically LAS and ATX, we calcu-
lated odds ratios for combination therapy from patient
characteristics. A number of these factors were associated
with combination therapy. These included being older,
having psychiatric care, and having comorbid depression.
The association between psychiatric care and combina-
tion therapy is not surprising given that patients with
more severe or treatment refractory disease are more likely
to be referred for psychiatric care after having failed 1 or
more simpler treatment regimens.
In contrast to previous models where the decision to ini-
tiate ATX rather than LAS was associated with claims his-
tories suggesting high comorbidities and clinical
complexity [20], the pattern of factors predicting rates of
combination therapy were mostly similar for both ATX
and LAS. The most salient difference between the current
models was the hyperactive component of ADHD. Hyper-
active component was not a significant predictor of com-
bination therapy for LAS, despite the very large sample
size and tighter confidence interval. The hyperactive com-
ponent was significantly associated with increased combi-
nation therapy for ATX. While the prevalence and
significance of hyperactive symptoms in adults is unclear,
there is some evidence [21] that hyperactive symptoms in
children with ADHD may be less likely to persist into
adulthood than inattentive symptoms. Another impor-
tant finding is that patients with HMO insurance plans
rather than point-of-service coverage were less likely to
receive additional medications for ADHD with LAS. The
reason for this difference is unknown, but could indicate
Table 3: Percent of Months of Treatment in which Multiple ADHD Medications were Prescribed
Drug Class
(number of months of therapy excluding first months)
LAS IAS SAS ATX BUP A2A Any other ADHD medication
LAS (34,239) 79.0 1.0 9.5 1.9 9.3 1.1 21.0
IAS (11,200) 2.5 72.6 17.1 1.1 8.4 0.8 27.4
SAS (31,239) 9.1 5.9 76.9 1.5 7.8 1.0 23.1
ATX (8,141) 6.7 1.0 4.7 80.3 8.6 1.0 19.7
BUP (18,318) 17.0 5.0 13.5 4.4 63.1 1.2 36.9
A2A (1,639) 22.3 5.5 18.3 5.7 12.2 47.0 53.0
Rows represent therapy of focus. Percents represent breakout of proportion of months in combination with other therapies. Numbers on the 
diagonal from top left to lower right represent number of months on monotherapy on Long-Acting Stimulants (LAS), Intermediate-Acting 
Stimulants (IAS), Short-Acting Stimulants (SAS), Atomoxetine (ATX), Bupropion (BUP), and Alpha-2 Adrenergic Agonists (A2A). Row sums across 
individual drug classes may be larger than the value shown for combination with any class due to more than 2 classes being prescribed in 
combination.BMC Health Services Research 2009, 9:95 http://www.biomedcentral.com/1472-6963/9/95
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Adjusted Odds Ratio for 2 Models, Long-Acting Stimulants and Atomoxetine Figure 1
Adjusted Odds Ratio for 2 Models, Long-Acting Stimulants and Atomoxetine. Adjusted odds ratios (confidence 
intervals) for combination therapy use in 2 models, long-acting stimulants (LAS) and atomoxetine (ATX) in adults with ADHD.BMC Health Services Research 2009, 9:95 http://www.biomedcentral.com/1472-6963/9/95
Page 7 of 8
(page number not for citation purposes)
that HMOs are more likely to discourage the use of com-
bination therapy in an effort to reduce costs.
As described above, combination therapy in adult psychi-
atry is not uncommon and is fairly well documented in
depression and schizophrenia [14-17]. Combination
therapy is not as well understood in patients diagnosed
with adult ADHD, although the results of a recent chart
review [18] and present findings indicate that it is fairly
prevalent and varies depending upon the medications
prescribed. Regardless of the diagnosis, combination ther-
apy should be reserved for severe cases or treatment-resist-
ant patients. The results of this study suggest that the
medications used most often in monotherapy are LAS and
ATX. Using a single medication is beneficial to patients for
both physical (e.g., having fewer side effects from 1 med-
ication versus multiple medications) and financial (e.g.,
cost of 1 versus multiple medications) reasons.
The management of patients with adult ADHD can be
complex. In making treatment decisions, clinicians must
evaluate the unique characteristics of patients as well as
the distinct benefits and risks of different treatment
options. For example, although stimulants are very effec-
tive in treating ADHD, they have significant abuse poten-
tial [7,19]. In patients with histories of substance abuse or
dependence (or who may live with those who do), diver-
sion potential becomes a concern and may influence
treatment selection. On the other hand, in a randomized,
placebo-controlled, head-to-head trial of atomoxetine
versus osmotically-released methylphenidate, Newcorn
and colleagues (2008) concluded that while patients in
the atomoxetine group (n = 222) and the osmotically-
released methylphenidate group (n = 220) both showed
significant superiority to placebo on the ADHD-RS pri-
mary endpoint measure after 6 weeks, clinical response to
osmotically-released methylphenidate was superior to the
response to atomoxetine (56% vs. 45%, respectively) [22].
Further, although medications can control the core symp-
toms of ADHD, the use of cognitive or behavioral thera-
pies is also beneficial in managing this disorder [23].
Future research should examine the influence of these
therapies on the need for combination therapy, or lack
thereof, in adult ADHD patients.
Limitations
Although these findings provide initial data on combina-
tion therapy in adult ADHD, several limitations need to
be acknowledged. Claims data are collected for adminis-
trative purposes and cannot be considered as accurate or
reliable as data collected for a specific scientific purpose.
Second, the provider type "psychiatrist" is imputed within
the PharMetrics database and may include some psychol-
ogists and social workers billing for services typical of psy-
chiatrists. The attribution of a claims history of prior
psychiatric visit is, therefore, somewhat imprecise. Third,
formulary status, plan restrictions, and tier status were not
known and may have influenced the associations
described here. Fourth, although these data indicate that
LAS and ATX are least likely to be associated with combi-
nation therapy in ADHD, direct evidence of effectiveness
(i.e., reduction in ADHD symptomatology) is not availa-
ble in this dataset. Fifth, from the perspective of generaliz-
ability, patients from the Midwest and South are
overrepresented in this sample, so care should be taken in
generalizing too broadly. Finally, although the sample
was restricted to patients with a previous claim diagnosis
of ADHD, one is not able to conclusively determine the
reason for each individual pharmaceutical claim.
Conclusion
This study suggests that only a small percentage, 6.1% of
the adult patients with a history of ADHD, receive any
pharmacological treatment during the course of a year.
LAS and ATX are the most common pharmacological
monotherapies in the treatment of adult ADHD. IAS and
SAS were used more frequently in combination with other
medications while BUP (an atypical antidepressant) and
A2A (antihypertensives that are also used on occasion to
promote sleep) were most often to be used in combina-
tion with other medications. Factors predicting combina-
tion use (personal, clinical, and health care delivery
factors) were similar for months in which ATX was used
and for months in which LAS were used, except that a
hyperactive component to ADHD predicted increased
combination use for ATX but not for LAS. Further research
is needed to better understand the motivations for combi-
nation therapy in managing adult ADHD, particularly in
terms of symptom outcomes and nonpharmacological
treatments used for ADHD.
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These data were previously presented in poster format at the 2006 Amer-
ican Psychiatric Association Convention in Toronto, ON, Canada (May 20–
25, 2006).
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